<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>Strength of Evidence</title>

<script src="site_libs/header-attrs-2.14/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.11.4/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>
<link href="site_libs/anchor-sections-1.1.0/anchor-sections.css" rel="stylesheet" />
<link href="site_libs/anchor-sections-1.1.0/anchor-sections-hash.css" rel="stylesheet" />
<script src="site_libs/anchor-sections-1.1.0/anchor-sections.js"></script>
<script src="site_libs/kePrint-0.0.1/kePrint.js"></script>
<link href="site_libs/lightable-0.0.1/lightable.css" rel="stylesheet" />

<link rel="icon" href="https://github.com/workflowr/workflowr-assets/raw/main/img/reproducible.png">
<!-- Add a small amount of space between sections. -->
<style type="text/css">
div.section {
  padding-top: 12px;
}
</style>



<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark it active
  menuAnchor.tab('show');

  // if it's got a parent navbar menu mark it active as well
  menuAnchor.closest('li.dropdown').addClass('active');

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "&#xe258;";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">NMB</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="soe.html">Strength of Evidence</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    NMM Technical
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="kq1.html">Results</a>
    </li>
    <li>
      <a href="summary_tech.html">Summary Study &amp; Patient Charcteristics</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    NMM Diagnostic
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="kq2.html">Results</a>
    </li>
    <li>
      <a href="summary_kq2.html">Summary Study &amp; Patient Charcteristics</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    NMM Outcomes
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="kq3.html">Results</a>
    </li>
    <li>
      <a href="tofr_confirm.html">TOFR Confirmed Before Extubation</a>
    </li>
    <li>
      <a href="summary_kq3.html">Summary Study &amp; Patient Charcteristics</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Reversal
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="reversal.html">Sugammadex vs. Neostigmine</a>
    </li>
    <li>
      <a href="summary_rev.html">Summary Study &amp; Patient Charcteristics</a>
    </li>
  </ul>
</li>
<li>
  <a href="evidence_tables.html">Evidence Tables</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Appendices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="prisma.html">PRISMA</a>
    </li>
    <li>
      <a href="outcome_importance.html">Outcome Importance</a>
    </li>
  </ul>
</li>
<li>
  <a href="about.html">About</a>
</li>
<li>
  <a href="license.html">License</a>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">Strength of Evidence</h1>
<h4 class="date">05 May, 2022 (19:58)</h4>

</div>


<style type="text/css">
  body{
  font-size: 9.5pt;
  font-family: Source Sans Pro;
}

.list-group-item.active, .list-group-item.active:hover, .list-group-item.active:focus {
  color: #090909;
  background-color: #0909093d;
}

.lightable-classic.lightable-hover tbody tr:hover {
    background-color: #c5d4e4;
}
.btn-xs, .btn-group-xs>.btn { 
display: none; 
}

.btn-default {
display: none !important; 
}

@font-face {
    font-family: "GRADE-quality";
    src: url();
    src: url('https://gradepro.org/fonts/GRADE-quality.eot');
    src: url('https://gradepro.org/fonts/GRADE-quality.eot?#iefix')
        format('embedded-opentype'),
      url('https://gradepro.org/fonts/GRADE-quality.woff') format('woff'),
      url('https://gradepro.org/fonts/GRADE-quality.ttf') format('truetype'),
      url('https://gradepro.org/fonts/GRADE-quality.svg#GRADE-quality')
        format('svg');
    font-weight: normal;
    font-style: normal;
}

.quality-sign {
      font-family: 'GRADE-quality', Cambria, Helvetica, Arial;
      font-size: 10px;
      vertical-align: text-top;
    }

span { font-size: 3em;}

span b { font-size: 60%; font-weight: normal }


</style>
<p><font size = 4> Ratings for important outcomes according to study
design.</font></p>
<div id="nmm-technical-performance" class="section level1 hasAnchor">
<h1 class="hasAnchor"><strong>NMM Technical Performance</strong><a
href="#nmm-technical-performance" class="anchor-section"
aria-label="Anchor link to header"></a></h1>
<p><br/></p>
<div id="strength-of-evidence-ratings" class="section level3 hasAnchor">
<h3 class="hasAnchor">Strength of Evidence Ratings<a
href="#strength-of-evidence-ratings" class="anchor-section"
aria-label="Anchor link to header"></a></h3>
<p><br/></p>
<p><font size = 4> Table 1. Strength of evidence for outcomes relevant
to neuromuscular monitor technical performance. </font></p>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; border-bottom: 0;">
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="1">
<div style="">
Studies
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="2">
<div style="">
Strength of Evidence
</div>
</th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="2">
</th>
</tr>
<tr>
<th style="text-align:left;font-weight: bold;">
Outcome
</th>
<th style="text-align:center;font-weight: bold;">
(pts)
</th>
<th style="text-align:left;font-weight: bold;">
 GRADE
</th>
<th style="text-align:center;font-weight: bold;">
ACC/AHA
</th>
<th style="text-align:center;font-weight: bold;">
Importance<sup>1</sup>
</th>
<th style="text-align:left;font-weight: bold;">
       Summary
</th>
<th style="text-align:left;font-weight: bold;">
Result Detail
</th>
</tr>
</thead>
<tbody>
<tr grouplength="6">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Fully Paired</strong>
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicus vs. Corrigator Supercilii</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR <br> ≥ 0.9 or 1.0
</td>
<td style="text-align:center;width: 5em; ">
4 <br>(140)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Two of 3 fully paired studies and 1 RCT reported shorter times to TOFR ≥
0.9 or ≥1.0 when measured at the corrigator supercilii vs. adductor
pollicis. This finding was consistent in patients recovering
spontaneously or administered sugammadex, and in young adults and
elderly (≥70 yrs). One small fully paired study did not detect a
difference.
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicus vs. Orbicularis Oculi</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR <br> ≥ 0.8 or 0.9
</td>
<td style="text-align:center;width: 5em; ">
2 <br>(46)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Two fully paired studies (spontaneous reversal or neostigmine) reported
shorter times to TOFR ≥ 0.8 or ≥0.9 when measured at the obicularis
oculi vs. adductor pollicis.
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicus vs. Masseter</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR <br> ≥ 0.9
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(10)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One fully paired study (n=10) did not detect a difference in time to
TOFR ≥ 0.9 when measured at the masseter vs. adductor pollicis in
patients recovering spontaneously.
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicus vs. Flexor Hallucis Brevis</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR <br> ≥0.9
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(52)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One fully paired study reported shorter times to TOFR ≥ 0.9 when
measured at the flexor hallucis brevis vs. adductor poliicis in patients
recovering spontaneously. A difference was not detected in patients
administered neostigmine.
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Flexor Hallucis Brevis vs. First Dorsal Interosseous</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR <br> ≥ 0.9
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(29)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One fully paired study reported shorter time to TOFR ≥ 0.9 when measured
at the flexor hallucis brevis vs. first dorsal interosseous among
patients recovering spontaneously.
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Normalization vs. No Normalization</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
RNMB
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(122)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One fully paired study reported more frequent RNMB (TOFR &lt; 1.0) when
using normalized measures vs. non-normalized measures. A difference was
not detected in severe RNMB (TOFR &lt; 0.7).
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Prospective Cohort</strong>
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicus vs. Orbicularis Oculi</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
RNMB
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(150)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
One prospective cohort study reported more freqent RNMB when obicularis
oculi is monitored vs. adductor policis, OR 5.5 (95% CI, 2.1-14.5).
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; " colspan="100%">
<sup></sup> RNMB: residual neuromuscular blockade; TOFR: train of four
ratio; OR: odds ratio.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>1</sup> ● Limited, ●● Important, ●●● Critical.
</td>
</tr>
</tfoot>
</table>
<p><br/></p>
</div>
<div id="grade-domains" class="section level3 hasAnchor">
<h3 class="hasAnchor">GRADE Domains<a href="#grade-domains"
class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p><br></p>
<p><font size = 4> Table 2. GRADE domains for strength of evidence
rating for outcomes relevant to neuromuscular monitor technical
performance. </font></p>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; width: auto !important; border-bottom: 0;">
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="2">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
Studies
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="5">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
Domains
</div>
</th>
</tr>
<tr>
<th style="text-align:left;font-weight: bold;">
Outcome
</th>
<th style="text-align:left;font-weight: bold;">
Design
</th>
<th style="text-align:left;font-weight: bold;">
N (pts)
</th>
<th style="text-align:left;font-weight: bold;">
Bias
</th>
<th style="text-align:left;font-weight: bold;">
Inconsistency
</th>
<th style="text-align:left;font-weight: bold;">
Indirectness
</th>
<th style="text-align:left;font-weight: bold;">
Imprecision
</th>
<th style="text-align:left;font-weight: bold;">
Other
</th>
</tr>
</thead>
<tbody>
<tr grouplength="6">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Fully Paired</strong>
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicus vs. Corrigator Supercilii</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR <br> ≥ 0.9 or 1.0
</td>
<td style="text-align:left;width: 4em; ">
Fully_paired (3) and rct (1)
</td>
<td style="text-align:left;width: 10em; ">
4 (140)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>1</sup>
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicus vs. Orbicularis Oculi</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR <br> ≥ 0.8 or 0.9
</td>
<td style="text-align:left;width: 4em; ">
Fully_paired
</td>
<td style="text-align:left;width: 10em; ">
2 (46)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>2</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>3</sup>
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicus vs. Masseter</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR <br> ≥ 0.9
</td>
<td style="text-align:left;width: 4em; ">
Fully_paired
</td>
<td style="text-align:left;width: 10em; ">
1 (10)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>4</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>5</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicus vs. Flexor Hallucis Brevis</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR <br> ≥0.9
</td>
<td style="text-align:left;width: 4em; ">
Fully_paired
</td>
<td style="text-align:left;width: 10em; ">
1 (52)
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>6</sup>
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>4</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>7</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Flexor Hallucis Brevis vs. First Dorsal Interosseous</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR <br> ≥ 0.9
</td>
<td style="text-align:left;width: 4em; ">
Fully_paired
</td>
<td style="text-align:left;width: 10em; ">
1 (29)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>4</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>8</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Normalization vs. No Normalization</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
RNMB
</td>
<td style="text-align:left;width: 4em; ">
Fully_paired
</td>
<td style="text-align:left;width: 10em; ">
1 (122)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>4</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>9</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>7</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Prospective Cohort</strong>
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Adductor Pollicus vs. Orbicularis Oculi</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
RNMB
</td>
<td style="text-align:left;width: 4em; ">
Pro_cohort
</td>
<td style="text-align:left;width: 10em; ">
1 (150)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>4</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>9</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>10</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; " colspan="100%">
<sup></sup> RCT: randomized controlled trial; NRSI: nonrandomized study
of interventions.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>1</sup> Methodological heterogeneity: spontaneous/sugammadex; TOFR
threshold.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>2</sup> Overlapping distributions in one of the two studies.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>3</sup> Methodological heterogeneity.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>4</sup> Single study, cannot assess consistency.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>5</sup> Estimate has large standard deviation; small sample size
(n=10).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>6</sup> 13% excluded from analysis due to missing data and protocol
deviation.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>7</sup> Estimates have large standard deviations.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>8</sup> Estimate has large standard deviation.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>9</sup> Intermediate outcome.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>10</sup> Estimate has wide confidence interval.
</td>
</tr>
</tfoot>
</table>
<p><br/></p>
<hr style="height:2px;border-width:0;color:gray;background-color:gray">
<p><br/></p>
<p><br/></p>
</div>
</div>
<div id="nmm-outcomes" class="section level1 hasAnchor">
<h1 class="hasAnchor"><strong>NMM Outcomes</strong><a
href="#nmm-outcomes" class="anchor-section"
aria-label="Anchor link to header"></a></h1>
<p><br/></p>
<div id="strength-of-evidence-ratings-1"
class="section level3 hasAnchor">
<h3 class="hasAnchor">Strength of Evidence Ratings<a
href="#strength-of-evidence-ratings-1" class="anchor-section"
aria-label="Anchor link to header"></a></h3>
<p><br/></p>
<p><font size = 4> Table 3. Strength of evidence for outcomes following
neuromuscular monitoring (evidence obtained from RCTs unless noted).
</font></p>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; border-bottom: 0;">
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="1">
<div style="">
Studies
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="2">
<div style="">
Strength of Evidence
</div>
</th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="2">
</th>
</tr>
<tr>
<th style="text-align:left;font-weight: bold;">
Outcome
</th>
<th style="text-align:center;font-weight: bold;">
(pts)
</th>
<th style="text-align:left;font-weight: bold;">
 GRADE
</th>
<th style="text-align:center;font-weight: bold;">
ACC/AHA
</th>
<th style="text-align:center;font-weight: bold;">
Importance<sup>1</sup>
</th>
<th style="text-align:left;font-weight: bold;">
       Summary
</th>
<th style="text-align:left;font-weight: bold;">
Result Detail
</th>
</tr>
</thead>
<tbody>
<tr grouplength="2">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Qualitative vs. Clinical</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
RNMB <br>TOFR &lt; 0.7
</td>
<td style="text-align:center;width: 5em; ">
3 <br>(158)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Less RNMB in patients with qualitative vs. clinical monitoring.<br>RR
0.38 (95% CI, 0.27–0.54), I<sup>2</sup> = 0%
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab4">Table 4</a><br> <a
href="kq3.html#kq3Fig1">Figure 1</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Mean TOFR
</td>
<td style="text-align:center;width: 5em; ">
4 <br>(268)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Three of 4 RCTs reported higher mean TOFR at extubation or in the PACU
in patients with qualitative monitoring vs. clinical. One did not detect
a difference.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab6">Table 6</a>
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Clinical</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
RNMB <br>TOFR &lt; 0.7 to 0.9
</td>
<td style="text-align:center;width: 5em; ">
3 <br>(232)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Less RNMB in patients with quantitative vs. clinical monitoring.<br> RR
0.18 (95% CI, 0.06–0.50) , I<sup>2</sup> = 0%
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab4">Table 4</a><br> <a
href="kq3.html#kq3Fig2">Figure 2</a>
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Qualitative</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
RNMB <br>TOFR &lt; 0.9
</td>
<td style="text-align:center;width: 5em; ">
2 <br>(329)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Less RNMB in patients with quantitative vs. qualitative
monitoring.<br>RR 0.24 (95% CI, 0.13–0.43) , I<sup>2</sup> = 18%
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab4">Table 4</a><br> <a
href="kq3.html#kq3Fig3">Figure 3</a>
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Qualitative vs. Clinical</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
RNMB <br>TOFR &lt; 0.7 to 0.9
</td>
<td style="text-align:center;width: 5em; ">
11 <br>(1211)
</td>
<td style="text-align:left;width: 6em; ">
Not rated<sup>2</sup>
</td>
<td style="text-align:center;width: 6em; ">
Not rated
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Quantitative vs. qualitative monitoring.<br> RR 0.40 (95% CI, 0.3–0.55)
<br> Quantitative monitoring vs. clinical assessment.<br>RR 0.15 (95%
CI, 0.10–0.22)
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab5">Table 5</a><br> <a
href="kq3.html#kq3Fig5">Figure 5</a>
</td>
</tr>
<tr grouplength="2">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Qualitative or Clinical</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Mean TOFR
</td>
<td style="text-align:center;width: 5em; ">
3 <br>(262)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Two of 3 RCTs reported higher mean TOFR at extubation or in the PACU in
patients with quantitative monitoring vs. qualitative or clinical. One
RCT did not detect a difference.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab6">Table 6</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Hypoxia
</td>
<td style="text-align:center;width: 5em; ">
3 <br>(419)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Two of 3 RCTs reported less hypoxia in patients with quantitative
monitoring vs. qualitative or clinical. One RCT reported no events.
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab7">Table 7</a>
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Qualitative</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Pulmonary Complications
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(6868)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Difference not detected in pulmonary complications in patients with
quantitative monitoring vs. qualitative or clinical. <br>Adjusted OR
1.07 (95% CI, 0.90–1.29)
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab7">Table 7</a>
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Any monitoring vs. none</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Pulmonary Complications
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(17150)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
More pulmonary complications in patients with any monitoring vs. none.
<br> Adjusted OR 1.31 (95% CI, 1.15–1.49)
</td>
<td style="text-align:left;width: 7em; ">
<a href="kq3.html#kq3Tab7">Table 7</a>
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; " colspan="100%">
<sup></sup> RNMB: residual neuromuscular blockade; TOFR: train of four
ratio; RR: risk ratio.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>1</sup> ● Limited, ●● Important, ●●● Critical.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>2</sup> Not rated as obtained from network meta-analysis agnostic
of study design. However, consistency of effects with that from the
randomized designs alone could argue for rating up the strength of
evidence.
</td>
</tr>
</tfoot>
</table>
<p><br/></p>
</div>
<div id="grade-domains-1" class="section level3 hasAnchor">
<h3 class="hasAnchor">GRADE Domains<a href="#grade-domains-1"
class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p><br></p>
<p><font size = 4> Table 4. GRADE domains for strength of evidence
ratings relevant to outcomes with neuromuscular monitoring. </font></p>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; width: auto !important; border-bottom: 0;">
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="2">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
Studies
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="5">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
Domains
</div>
</th>
</tr>
<tr>
<th style="text-align:left;font-weight: bold;">
Outcome
</th>
<th style="text-align:left;font-weight: bold;">
Design
</th>
<th style="text-align:left;font-weight: bold;">
N (pts)
</th>
<th style="text-align:left;font-weight: bold;">
Bias
</th>
<th style="text-align:left;font-weight: bold;">
Inconsistency
</th>
<th style="text-align:left;font-weight: bold;">
Indirectness
</th>
<th style="text-align:left;font-weight: bold;">
Imprecision
</th>
<th style="text-align:left;font-weight: bold;">
Other
</th>
</tr>
</thead>
<tbody>
<tr grouplength="2">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Qualitative vs. Clinical</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
RNMB <br>TOFR &lt; 0.7
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
3 (158)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>1</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>2</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Mean TOFR
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
4 (268)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>3</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>1</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Clinical</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
RNMB <br>TOFR &lt; 0.7 to 0.9
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
3 (232)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>1</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>4</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Qualitative</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
RNMB <br>TOFR &lt; 0.9
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
2 (329)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>1</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>4</sup>
</td>
<td style="text-align:left;width: 8em; ">
note<sup>7</sup>
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Qualitative vs. Clinical</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
RNMB <br>TOFR &lt; 0.7 to 0.9
</td>
<td style="text-align:left;width: 4em; ">
8 RCTs, 1 quasi-experimental, and 2 cohort
</td>
<td style="text-align:left;width: 10em; ">
11 (1211)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>9</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>10</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>11</sup>
</td>
</tr>
<tr grouplength="2">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Qualitative or Clinical</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Mean TOFR
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
3 (262)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>12</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>1</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Hypoxia
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
3 (419)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>1</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>13</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>14</sup>
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Quantitative vs. Qualitative</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Pulmonary Complications
</td>
<td style="text-align:left;width: 4em; ">
Prospective Cohort
</td>
<td style="text-align:left;width: 10em; ">
1 (6868)
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>15</sup>
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>5</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="8" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Any monitoring vs. none</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Pulmonary Complications
</td>
<td style="text-align:left;width: 4em; ">
Prospective Cohort
</td>
<td style="text-align:left;width: 10em; ">
1 (17150)
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>15</sup>
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>5</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>1</sup> Sugammadex not used in any trial.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>2</sup> Sufficient events given effect size and control incidence.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>3</sup> Three of 4 RCTs reported higher mean TOFR in patients with
qualitative monitoring vs. clinical. One did not detect a difference.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>4</sup> Wide confidence interval, but does does not cross the
decision treatment threshold.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>5</sup> Single study, cannot assess consistency.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>6</sup> Limited number of events.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>7</sup> Large effect but based on 2 trials from same investigators.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>8</sup> Sugammadex not used.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>9</sup> Low heterogeneity (I<sup>2</sup> = 25%).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>10</sup> Sugammadex used in one observational study.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>11</sup> Large effects with methodological heterogeneity related to
different study designs and TOFR thresholds.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>12</sup> Two of 3 RCTs reported higher mean TOFR in patients with
quantitative monitoring vs. either qualitative or clinical. One did not
detect a difference.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>13</sup> Limited number of events.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>14</sup> Methodological heterogeneity: different thresholds for
hypoxia.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>15</sup> Multicenter observational study with use of neuromuscular
blocking agents, reversal, and monitoring at the centers’ discretion.
</td>
</tr>
</tfoot>
</table>
<p><br/></p>
<hr style="height:2px;border-width:0;color:gray;background-color:gray">
<p><br/></p>
</div>
</div>
<div id="nmm-confirm-tofr-before-extubation"
class="section level1 hasAnchor">
<h1 class="hasAnchor"><strong>NMM Confirm TOFR Before
Extubation</strong><a href="#nmm-confirm-tofr-before-extubation"
class="anchor-section" aria-label="Anchor link to header"></a></h1>
<p><br/></p>
<div id="strength-of-evidence-ratings-2"
class="section level3 hasAnchor">
<h3 class="hasAnchor">Strength of Evidence Ratings<a
href="#strength-of-evidence-ratings-2" class="anchor-section"
aria-label="Anchor link to header"></a></h3>
<p><br/></p>
<p><font size = 4> Table 5. Strength of evidence for TOFR confirmation
prior to extubation.</font></p>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; border-bottom: 0;">
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="1">
<div style="">
Studies
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="2">
<div style="">
Strength of Evidence
</div>
</th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="2">
</th>
</tr>
<tr>
<th style="text-align:left;font-weight: bold;">
Outcome
</th>
<th style="text-align:center;font-weight: bold;">
(pts)
</th>
<th style="text-align:left;font-weight: bold;">
 GRADE
</th>
<th style="text-align:center;font-weight: bold;">
ACC/AHA
</th>
<th style="text-align:center;font-weight: bold;">
Importance<sup>1</sup>
</th>
<th style="text-align:left;font-weight: bold;">
       Summary
</th>
<th style="text-align:left;font-weight: bold;">
Result Detail
</th>
</tr>
</thead>
<tbody>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>      Sugammadex</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
RNMB TOFR &lt; 0.9
</td>
<td style="text-align:center;width: 5em; ">
26 <br>(2289)
</td>
<td style="text-align:left;width: 6em; ">
Moderate
</td>
<td style="text-align:center;width: 6em; ">
B-NR
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
A lower incidence of residual neuromuscular blockade (TOFR &lt; 0.9) was
observed in study arms when TOFR ≥ 0.9 was confirmed prior to
extubation. The estimated incidence of residual neuromuscular blockade
with confirmation was 0.3/100 (95% CI: 0, 1.2); without confirmation 3.7
(95% CI: 0.6, 9.4). Risk ratio 0.07 (95% CI: 0.00, 0.56) comparing
confirmation with no confirmation. Accounting for study reports where it
was unclear if TOFR was confirmed prior to extubation in sensitivity
analyses did not alter the certainty.
</td>
<td style="text-align:left;width: 7em; ">
<a href="tofr_confirm.html#confTab1">Table 1</a><br> <a
href="tofr_confirm.html#confFig1">Figure 1</a>
</td>
</tr>
<tr grouplength="1">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>      Neostigmine</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
RNMB TOFR &lt; 0.9
</td>
<td style="text-align:center;width: 5em; ">
31 <br>(2167)
</td>
<td style="text-align:left;width: 6em; ">
Moderate
</td>
<td style="text-align:center;width: 6em; ">
B-NR
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
A lower incidence of residual neuromuscular blockade (TOFR &lt; 0.9) was
observed in study arms when TOFR ≥ 0.9 was confirmed prior to
extubation. The estimated incidence proportion of residual neuromuscular
blockade with confirmation was 5.0/100 (95% CI: 1.3, 10.9); without
confirmation 39.2/100 (95% CI: 19.5, 60.9). Risk ratio 0.13 (95% CI:
0.04, 0.32) comparing confirmation to no confirmation. Accounting for
study reports where it was unclear if TOFR was confirmed prior to
extubation in sensitivity analyses did not alter the certainty.
</td>
<td style="text-align:left;width: 7em; ">
<a href="tofr_confirm.html#confTab2">Table 2</a><br> <a
href="tofr_confirm.html#confFig2">Figure 2</a>
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; " colspan="100%">
<sup></sup> OR: odds ratio; MD: mean difference; RCT: randomized
controlled trial; NRSI: nonrandomized study of interventions.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>1</sup> ● Limited, ●● Important, ●●● Critical.
</td>
</tr>
</tfoot>
</table>
<p><br/></p>
</div>
<div id="grade-domains-2" class="section level3 hasAnchor">
<h3 class="hasAnchor">GRADE Domains<a href="#grade-domains-2"
class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p><br></p>
<p><font size = 4> Table 6. GRADE domains for strength of evidence
ratings for TOFR confirmation prior to extubation.</font></p>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; width: auto !important; border-bottom: 0;">
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="2">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
Studies
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="5">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
Domains
</div>
</th>
</tr>
<tr>
<th style="text-align:left;font-weight: bold;">
Outcome
</th>
<th style="text-align:left;font-weight: bold;">
Design
</th>
<th style="text-align:left;font-weight: bold;">
N (pts)
</th>
<th style="text-align:left;font-weight: bold;">
Bias
</th>
<th style="text-align:left;font-weight: bold;">
Inconsistency
</th>
<th style="text-align:left;font-weight: bold;">
Indirectness
</th>
<th style="text-align:left;font-weight: bold;">
Imprecision
</th>
<th style="text-align:left;font-weight: bold;">
Other
</th>
</tr>
</thead>
<tbody>
<tr grouplength="3">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Sugammadex vs. Neostigmine</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
RNMB TOFR &lt; 0.9
</td>
<td style="text-align:left;width: 4em; ">
Any
</td>
<td style="text-align:left;width: 10em; ">
26 (2289)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
rate up<sup>1</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
RNMB TOFR &lt; 0.9
</td>
<td style="text-align:left;width: 4em; ">
Any
</td>
<td style="text-align:left;width: 10em; ">
31 (2167)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>2</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>3</sup>
</td>
<td style="text-align:left;width: 8em; ">
rate up<sup>1</sup>
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>1</sup> Strong relative effect.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>2</sup> Alghough incidence rates varied, within TOFR confirmation
groups the confidence intervals for individual studies and pooled
estimates offered consistent decision informative estimates.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>3</sup> The confidence intervals provide sufficient certainty with
respect to decision implications.
</td>
</tr>
</tfoot>
</table>
<p><br/></p>
<hr style="height:2px;border-width:0;color:gray;background-color:gray">
<p><br/></p>
</div>
</div>
<div id="reversal" class="section level1 hasAnchor">
<h1 class="hasAnchor"><strong>Reversal</strong><a href="#reversal"
class="anchor-section" aria-label="Anchor link to header"></a></h1>
<p><a id="soeReversal"></a></p>
<p><br/></p>
<div id="strength-of-evidence-ratings-3"
class="section level3 hasAnchor">
<h3 class="hasAnchor">Strength of Evidence Ratings<a
href="#strength-of-evidence-ratings-3" class="anchor-section"
aria-label="Anchor link to header"></a></h3>
<p><br/></p>
<p><font size = 4> Table 7. Strength of evidence for reversal outcomes
comparing sugammadex with neostigmine.</font></p>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; border-bottom: 0;">
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="1">
<div style="">
Studies
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="2">
<div style="">
Strength of Evidence
</div>
</th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="2">
</th>
</tr>
<tr>
<th style="text-align:left;font-weight: bold;">
Outcome
</th>
<th style="text-align:center;font-weight: bold;">
(pts)
</th>
<th style="text-align:left;font-weight: bold;">
 GRADE
</th>
<th style="text-align:center;font-weight: bold;">
ACC/AHA
</th>
<th style="text-align:center;font-weight: bold;">
Importance<sup>1</sup>
</th>
<th style="text-align:left;font-weight: bold;">
       Summary
</th>
<th style="text-align:left;font-weight: bold;">
Result Detail
</th>
</tr>
</thead>
<tbody>
<tr grouplength="3">
<td colspan="7" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Sugammadex vs. Neostigmine</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
RNMB TOFR &lt; 0.9
</td>
<td style="text-align:center;width: 5em; ">
8 <br>(1143)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
A
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Less RNMB (TOFR &lt; 0.9) among patients reversed with sugammadex
vs. neostigmine. <br> RR 0.18 (95% CI, 0.07–0.42; I<sup>2</sup> = 65%)
<br> RD -23.5% (95% CI, -36.2% to -10.8%), 9 studies
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab4">Table 4</a><br> <a
href="reversal.html#revFig2">Figure 2</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
RNMB TOFR &lt; 0.7
</td>
<td style="text-align:center;width: 5em; ">
4 <br>(637)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
A
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Less RNMB (TOFR &lt; 0.7) among patients reversed with sugammadex
vs. neostigmine.<br> RR 0.18 (95% CI, 0.08–0.39; I<sup>2</sup> = 14%)
<br> RD -16.0% (95% CI, -23.8% to -8.2%)
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab4">Table 4</a><br> <a
href="reversal.html#revFig3">Figure 3</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR ≥ 0.9 from deep NMB
</td>
<td style="text-align:center;width: 5em; ">
4 <br>(308)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
A
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Shorter time to TOFR ≥ 0.9 among patients reversed with sugammadex
vs. neostigmine from deep block.<br> MD minutes -33.6 (95% CI, -59.3 to
-7.9), 𝜏 = 25.7
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab8">Table 8</a><br> <a
href="reversal.html#revFig4">Figure 4</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR ≥ 0.9 from moderate block
</td>
<td style="text-align:center;width: 5em; ">
15 <br>(1010)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
A
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Shorter time to TOFR ≥ 0.9 among patients reversed with sugammadex
vs. neostigmine from moderate block. <br> MD -10.5 minutes (95% CI,
-13.3 to -7.6), 𝜏 = 5.5
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab8">Table 8</a><br> <a
href="reversal.html#revFig5">Figure 5</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR ≥ 0.9 from shallow block
</td>
<td style="text-align:center;width: 5em; ">
4 <br>(188)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Difference not detected in time to TOFR ≥ 0.9 among patients reversed
with sugammadex vs. neostigmine from shallow block. <br> MD -6.3 minutes
(95% CI, -11.0 to -1.6), 𝜏 = 4.7
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab8">Table 8</a><br> <a
href="reversal.html#revFig6">Figure 6</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Time to TOFR ≥ 0.9 from minimal block
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(17)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Single study shorter time to TOFR ≥ 0.9 among patients reversed with
sugammadex vs. neostigmine 40 mcg/kg from minimal block. <br> MD -1.4
minutes (95% CI, -2.0 to -0.8)
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab8">Table 8</a><br> <a
href="reversal.html#revFig7">Figure 7</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Anaphylaxis<br>(observational)
</td>
<td style="text-align:center;width: 5em; ">
5 <br>(114243)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Anaphylaxis was unreported with neostigmine (3 studies, 26051 patients).
<br>Among patients receiving sugammadex (5 studies, 88192 patients) the
pooled incidence was 1.6 per 10,000 (95% CI, 0.9–2.7), 𝜏 = 0.8.
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab13">Table 13</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Bradycardia
</td>
<td style="text-align:center;width: 5em; ">
15 <br>(1299)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
A
</td>
<td style="text-align:center;width: 5em; ">
●
</td>
<td style="text-align:left;width: 24em; ">
Lower rates of bradycardia among patients reversed with sugammadex
vs. neostigmine. <br> RD -9.1% (95% CI, -14.1% to -4.0%)
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab14">Table 14</a><br> <a
href="reversal.html#revFig9">Figure 9</a><br> <a
href="reversal.html#revFig10">Figure 10</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Tachycardia
</td>
<td style="text-align:center;width: 5em; ">
3 <br>(258)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●
</td>
<td style="text-align:left;width: 24em; ">
Difference not detected in tachycardia with sugammadex
vs. neostigmine.<br> RD 4.6% (95% CI, -0.9% to 10.1%)
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab15">Table 15</a><br> <a
href="reversal.html#revFig11">Figure 11</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Arrhythmias
</td>
<td style="text-align:center;width: 5em; ">
3 <br>(178)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●
</td>
<td style="text-align:left;width: 24em; ">
Difference not detected in arrhythmias with sugammadex
vs. neostigmine.<br> RD -1.2% (95% CI, -5.3% to 3.0%)
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab16">Table 16</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Postop nausea and vomiting
</td>
<td style="text-align:center;width: 5em; ">
14 <br>(1344)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●
</td>
<td style="text-align:left;width: 24em; ">
Less postoperative nausea and vomiting with sugammadex
vs. neostigmine.<br> RR 0.71 (95% CI, 0.54–0.95) <br> Difference not
detected for sugammadex vs. placebo/spontaneous recovery.<br> RR 0.66
(95% CI, 0.33-1.31)<br> Difference not detected for neostigmine
vs. placebo/spontaneous recovery.<br>RR 0.92 (95% CI, 0.48–1.77)
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab17">Table 17</a><br> <a
href="reversal.html#revFig13">Figure 13</a><br> <a
href="reversal.html#revTab18">Table 18</a><br> <a
href="reversal.html#revFig14">Figure 14</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Postop nausea
</td>
<td style="text-align:center;width: 5em; ">
28 <br>(2781)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●
</td>
<td style="text-align:left;width: 24em; ">
DIfference in post-operative nausea not detected for sugammadex
vs. neostigmine. <br> RR 0.93 (95% CI, 0.78–1.11) <br> DIfference not
detected for sugammadex vs. placebo/spontaneous recovery. <br> RR 0.95
(95% CI, 0.66–1.37) <br> DIfference not detected for neostigmine
vs. placebo/spontaneous recovery.<br> RR 1.02 (95% CI, 0.71–1.46)
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab19">Table 19</a><br> <a
href="reversal.html#revFig16">Figure 16</a><br> <a
href="reversal.html#revTab20">Table 20</a><br> <a
href="reversal.html#revFig17">Figure 17</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Postop vomiting
</td>
<td style="text-align:center;width: 5em; ">
18 <br>(1899)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●
</td>
<td style="text-align:left;width: 24em; ">
DIfference in post-operative vomiting not detected for sugammadex
vs. neostigmine. <br> RR 0.89 (95% CI, 0.64–1.23) <br> DIfference not
detected for sugammadex vs. placebo/spontaneous recovery. <br> RR 0.79
(95% CI, 0.44–1.40) <br> DIfference not detected for neostigmine
vs. placebo/spontaneous recovery.<br> RR 0.89 (95% CI, 0.53–1.49)
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab21">Table 21</a><br> <a
href="reversal.html#revFig19">Figure 19</a><br> <a
href="reversal.html#revTab22">Table 22</a><br> <a
href="reversal.html#revFig20">Figure 20</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Hypoxia<br> SaO<sub>2</sub> 90%
</td>
<td style="text-align:center;width: 5em; ">
7 <br>(670)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●
</td>
<td style="text-align:left;width: 24em; ">
Dfference in incidence of SaO<sub>2 </sub> ≤ 90% not deteted.<br>RD
-6.0% (95% CI, -18.2% to 6.2%), I<sup>2</sup> = 60%
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab23">Table 23</a><br> <a
href="reversal.html#revFig21">Figure 21</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Hypoxia <br> SaO<sub>2</sub> 90% to 95%
</td>
<td style="text-align:center;width: 5em; ">
7 <br>(792)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●
</td>
<td style="text-align:left;width: 24em; ">
Dfference in incidence of SaO<sub>2</sub> 90% to 95% not detected.<br>RD
1.6% (95% CI, -3.6% to 6.8%), I<sup>2</sup> = 0%
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab23">Table 23</a><br> <a
href="reversal.html#revFig21">Figure 21</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Pulmonary complications (composite)
</td>
<td style="text-align:center;width: 5em; ">
6 <br>(607)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Difference in incidence of pulmonary complication composite outcome
measure not detected. <br>OR 0.73 (95% CI, 0.51, 1.03), I<sup>2</sup> =
0%
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab24">Table 24</a><br> <a
href="reversal.html#revTab25">Table 25</a><br> <a
href="reversal.html#revTab26">Table 26</a><br> <a
href="reversal.html#revFig22">Figure 22</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Pulmonary complications (composite)<br>(nonrandomized)
</td>
<td style="text-align:center;width: 5em; ">
5 <br>(66716)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-NR
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Difference in incidence of pulmonary complication composite outcome
measure not detected. <br>OR 0.72 (95% CI, 0.41, 1.26), I<sup>2</sup> =
85%<br><br>Combined randomized and nonrandomized <br> OR 0.72 (95% CI,
0.55–0.95), I<sup>2</sup> = 64%
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab24">Table 24</a><br> <a
href="reversal.html#revFig22">Figure 22</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Pneumonia
</td>
<td style="text-align:center;width: 5em; ">
5 <br>(735)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">⨁</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Difference in the incidence of pneumonia not detected.<br> OR 0.49 (95%
CI, 0.20– 1.23), I<sup>2</sup> = 0%<br>RD -1.6% (95% CI, -4.3% to 1.1%),
𝜏 = 1.4%
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab25">Table 25</a> <br> <a
href="reversal.html#revFig23">Figure 23</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Pneumonia<br>(nonrandomized)
</td>
<td style="text-align:center;width: 5em; ">
3 <br>(56677)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
B-NR
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
Difference in the incidence of pneumonia not detected.<br> OR 0.68 (95%
CI, 0.40–1.16), I<sup>2</sup> = 76%<br><br>Combined randomized and
nonrandomized <br> OR 0.63 (95% CI, 0.41–0.98), I<sup>2</sup> = 39%
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab25">Table 25</a> <br> <a
href="reversal.html#revFig23">Figure 23</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Postoperative reintubation
</td>
<td style="text-align:center;width: 5em; ">
5 <br>(425)
</td>
<td style="text-align:left;width: 6em; ">
Low
</td>
<td style="text-align:center;width: 6em; ">
B-R
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
5 RCTs reported no postoperative reintubation with sugammadex and one
RCT reported 1 case with neostigmine. <br> Pooled RD -0.22% (95% CI,
-2.1% to 1.6%)
</td>
<td style="text-align:left;width: 7em; ">
<a
href="https://mdgrant.github.io/NMB/reversal.html#_Pneumonia_(adults)">Table
28</a><br> <a
href="https://mdgrant.github.io/NMB/reversal.html#____Pooled51">Figure
25</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Postoperative reintubation<br>(nonrandomized)
</td>
<td style="text-align:center;width: 5em; ">
4 <br>(18736)
</td>
<td style="text-align:left;width: 6em; ">
Very low
</td>
<td style="text-align:center;width: 6em; ">
B-NR
</td>
<td style="text-align:center;width: 5em; ">
●●●
</td>
<td style="text-align:left;width: 24em; ">
4 studies reported rates of postoperative reintubation with sugammadex
or neostigmine. <br> Pooled RD -1.7% (95% CI, -4.1% to 0.64%)
</td>
<td style="text-align:left;width: 7em; ">
<a
href="https://mdgrant.github.io/NMB/reversal.html#_Pneumonia_(adults)">Table
28</a><br> <a
href="https://mdgrant.github.io/NMB/reversal.html#____Pooled51">Figure
25</a>
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Recurarization
</td>
<td style="text-align:center;width: 5em; ">
10 <br>(552)
</td>
<td style="text-align:left;width: 6em; ">
Low
</td>
<td style="text-align:center;width: 6em; ">
B-NR
</td>
<td style="text-align:center;width: 5em; ">
●●
</td>
<td style="text-align:left;width: 24em; ">
9 of 10 trials reported no instances of recurarization; difference not
detected between sugammadex and neostigmine. <br> Pooled RD -1.6 per 100
(95% CI, -6.0 to 2.9)
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Atelectasis
</td>
<td style="text-align:center;width: 5em; ">
1 <br>(60)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●
</td>
<td style="text-align:left;width: 24em; ">
1 RCT reported 20% of patients developed atelectasis after neostigmine
vs. 0% after sugammadex.
</td>
<td style="text-align:left;width: 7em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 9em; ">
Bronchospasm
</td>
<td style="text-align:center;width: 5em; ">
3 <br>(367)
</td>
<td style="text-align:left;width: 6em; ">
<span><span class="quality-sign">⨁</span><span
class="quality-sign">◯</span><span class="quality-sign">◯</span><span
class="quality-sign">◯</span> </span>
</td>
<td style="text-align:center;width: 6em; ">
C-LD
</td>
<td style="text-align:center;width: 5em; ">
●●
</td>
<td style="text-align:left;width: 24em; ">
3 RCTs (6 events)<br>Pooled RD -0.3% (95% CI, -2.9% to 2.4%)
</td>
<td style="text-align:left;width: 7em; ">
<a href="reversal.html#revTab27">Table 27</a><br> <a
href="reversal.html#revFig24">Figure 24</a>
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; " colspan="100%">
<sup></sup> RNMB: residual neuromuscular blockade; RR: risk ratio; RD:
risk difference; OR: odds ratio; MD: mean difference; RCT: randomized
controlled trial; NRSI: nonrandomized study of interventions.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>1</sup> ● Limited, ●● Important, ●●● Critical.
</td>
</tr>
</tfoot>
</table>
<p><br/></p>
</div>
<div id="grade-domains-3" class="section level3 hasAnchor">
<h3 class="hasAnchor">GRADE Domains<a href="#grade-domains-3"
class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p><br></p>
<p><font size = 4> Table 8. GRADE domains for strength of evidence
ratings for reversal outcomes comparing sugammadex with neostigmine.
</font></p>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; width: auto !important; border-bottom: 0;">
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="2">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
Studies
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; font-weight: bold; " colspan="5">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
Domains
</div>
</th>
</tr>
<tr>
<th style="text-align:left;font-weight: bold;">
Outcome
</th>
<th style="text-align:left;font-weight: bold;">
Design
</th>
<th style="text-align:left;font-weight: bold;">
N (pts)
</th>
<th style="text-align:left;font-weight: bold;">
Bias
</th>
<th style="text-align:left;font-weight: bold;">
Inconsistency
</th>
<th style="text-align:left;font-weight: bold;">
Indirectness
</th>
<th style="text-align:left;font-weight: bold;">
Imprecision
</th>
<th style="text-align:left;font-weight: bold;">
Other
</th>
</tr>
</thead>
<tbody>
<tr grouplength="3">
<td colspan="8" style="border-bottom: 0px solid;color: #646971 !important;background-color: white !important;">
<strong>Sugammadex vs. Neostigmine</strong>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
RNMB TOFR &lt; 0.9
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
8 (1143)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>1</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>2</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>3</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
RNMB TOFR &lt; 0.7
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
4 (637)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>4</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>5</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>6</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR ≥ 0.9 from deep NMB
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
4 (308)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>7</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR ≥ 0.9 from moderate block
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
15 (1010)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>8</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR ≥ 0.9 from shallow block
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
4 (188)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>9</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>10</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Time to TOFR ≥ 0.9 from minimal block
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
1 (17)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>11</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>12</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Anaphylaxis<br>(observational)
</td>
<td style="text-align:left;width: 4em; ">
Obs
</td>
<td style="text-align:left;width: 10em; ">
5 (114243)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Bradycardia
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
15 (1299)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>13</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Tachycardia
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
3 (258)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>14</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Arrhythmias
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
3 (178)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>14</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>15</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Postop nausea and vomiting
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
14 (1344)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>16</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>17</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Postop nausea
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
28 (2781)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>16</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>18</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Postop vomiting
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
18 (1899)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>16</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>19</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Hypoxia<br> SaO<sub>2</sub> 90%
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
7 (670)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>20</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>21</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Hypoxia <br> SaO<sub>2</sub> 90% to 95%
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
7 (792)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>10</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Pulmonary complications (composite)
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
6 (607)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>10</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>22</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Pulmonary complications (composite)<br>(nonrandomized)
</td>
<td style="text-align:left;width: 4em; ">
Obs
</td>
<td style="text-align:left;width: 10em; ">
5 (66716)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>23</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>21</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>24</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Pneumonia
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
5 (735)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>14</sup>
</td>
<td style="text-align:left;width: 8em; ">
none
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Pneumonia<br>(nonrandomized)
</td>
<td style="text-align:left;width: 4em; ">
Obs
</td>
<td style="text-align:left;width: 10em; ">
3 (56677)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>25</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious<sup>26</sup>
</td>
<td style="text-align:left;width: 8em; ">
none<sup>27</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Postoperative reintubation
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
5 (425)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>28</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>29</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Postoperative reintubation<br>(nonrandomized)
</td>
<td style="text-align:left;width: 4em; ">
Obs
</td>
<td style="text-align:left;width: 10em; ">
4 (18736)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>30</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>31</sup>
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Recurarization
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
10 (552)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>32</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Atelectasis
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
1 (60)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>11</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>33</sup>
</td>
<td style="text-align:left;width: 8em; ">
serious<sup>34</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
</tr>
<tr>
<td style="text-align:left;width: 13em; ">
Bronchospasm
</td>
<td style="text-align:left;width: 4em; ">
RCT
</td>
<td style="text-align:left;width: 10em; ">
3 (367)
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
<td style="text-align:left;width: 8em; ">
very serious<sup>35</sup>
</td>
<td style="text-align:left;width: 8em; ">
not serious
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; " colspan="100%">
<sup></sup> RCT: randomized controlled trial; Obs: observational
(nonrandomized).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>1</sup> Wide prediction interval (I<sup>2</sup> = 65% for pooled
RR).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>2</sup> Wide confidence interval, but upper bound (0.42) would not
alter decision.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>3</sup> Methodological heterogeneity, but 3 trials did not report
depth of block. Large effect, not rated up owing to consideration of
precision.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>4</sup> Wide prediction interval (0.02–1.48).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>5</sup> Wide confidence interval, but upper bound (0.39) would not
alter decision.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>6</sup> Methodological heterogeneity, but 2 trials did not report
depth of block. Large effect, not rated up owing to consideration of
precision.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>7</sup> Wide prediction interval (-157 to 91), 𝜏 = 25.7.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>8</sup> Wide prediction interval (-22.7 to 1.8), 𝜏 = 5.5.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>9</sup> Wide prediction interval (-28.9 to 16.3), 𝜏 = 4.7.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>10</sup> Confidence interval crosses the null.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>11</sup> Single study, cannot assess consistency.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>12</sup> Insufficient sample size to assess.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>13</sup> Wide prediction interval (-8.2% To 26.4%).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>14</sup> Low event rate and confidence interval crosses the null.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>15</sup> No events reported for either agent.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>16</sup> Prediction interval crossing null for all comparisons in
network meta-analysis.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>17</sup> Comparison-adjusted funnel plot was consistent with small
study effects (potential for reporting or publication bias for either RR
or OR). 5 studies reported administering prophylactic antiemtics.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>18</sup> 6 studies reported administered prophylactic antiemtics.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>19</sup> 5 studies reported administered prophylactic antiemtics.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>20</sup> Wide prediction interval (-35.5 to 23.5).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>21</sup> Wide confidence interval crosses the null.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>22</sup> Methodological heterogeneity (overall downgraded two
levels in combination with inconsistency and precision).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>23</sup> Heterogeneity present, but attributable to small study.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>24</sup> Methodological heterogeneity.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>25</sup> Two large studies with discrepant results.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>26</sup> Large number of events.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>27</sup> POPULAR did not report incidence of pneumonia.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>28</sup> Confidence interval crossing the null. Low event rate.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>29</sup> Methodological heterogeneity (downgraded two levels in
combination with precision).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>30</sup> The 2 largest studies favored sugammadex.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>31</sup> Methodological diversity across studies.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>32</sup> Wide prediction interval (-15.3% to 12.2%).
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>33</sup> Postoperative pulmonary complications are complications of
residual neuromuscular blockade. Direct relationship to reversal agent?.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>34</sup> Low event rate.
</td>
</tr>
<tr>
<td style="padding: 0; " colspan="100%">
<sup>35</sup> Low event rate and wide confidence interval.
</td>
</tr>
</tfoot>
</table>
<p><br/></p>
<hr style="height:2px;border-width:0;color:gray;background-color:gray">
<p><a id="soeConfirm"></a></p>
<p><br/></p>
</div>
</div>
<div id="rating-systems-reference" class="section level1 hasAnchor">
<h1 class="hasAnchor"><strong>Rating Systems Reference</strong><a
href="#rating-systems-reference" class="anchor-section"
aria-label="Anchor link to header"></a></h1>
</div>
<div id="grade" class="section level1 hasAnchor">
<h1 class="hasAnchor">  GRADE<a href="#grade" class="anchor-section"
aria-label="Anchor link to header"></a></h1>
<p><br> <font size = 4> <strong>High</strong> — We are very confident
that the true effect lies close to that of the estimate of the
effect.</p>
<p><strong>Moderate</strong> — We are moderately confident in the effect
estimate: The true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially
different.</p>
<p><strong>Low</strong> — Our confidence in the effect estimate is
limited: The true effect may be substantially different from the
estimate of the effect.</p>
<p><strong>Very Low</strong> — We have very little confidence in the
effect estimate: The true effect is likely to be substantially different
from the estimate of effect.</p>
<p></font></p>
<div id="domains-downgrading" class="section level2 hasAnchor">
<h2 class="hasAnchor">Domains (downgrading)<a
href="#domains-downgrading" class="anchor-section"
aria-label="Anchor link to header"></a></h2>
<p><font size = 4></p>
<p><em>Bias</em> — Systematic error (eg, selection bias, confounding
bias, measurement bias).</p>
<p><em>Inconsistency</em> — Unexplained heterogeneity of results;
studies find effect estimates that differ widely.</p>
<p><em>Imprecision</em> — The range of plausible effects estimated from
relevant studies.</p>
<p><em>Indirectness</em> — Direct evidence consists of research that
directly compares the interventions which we are interested in,
delivered to the populations in which we are interested, and measures
the outcomes important to patients.</p>
<p><em>Other (eg, publication bias)</em> — Selective publication or
reporting of results (typically of positive results).</p>
</div>
<div id="domains-updgrading" class="section level2 hasAnchor">
<h2 class="hasAnchor">Domains (updgrading)<a href="#domains-updgrading"
class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p><em>Effect Size</em></p>
<p><em>Dose-response</em></p>
<p><em>Plausible Residual Confounding</em></p>
<p></font></p>
<p><br/><br/></p>
</div>
</div>
<div id="accaha" class="section level1 hasAnchor">
<h1 class="hasAnchor">  ACC/AHA<a href="#accaha" class="anchor-section"
aria-label="Anchor link to header"></a></h1>
<p><font size = 4></p>
<p><strong>Level A</strong> — High-quality evidence from more than 1
RCTs. Meta-analyses of high-quality RCTs. One or more RCTs corroborated
by high-quality registry studies.</p>
<p><strong>Level B-R</strong> — Moderate-quality evidence from 1 or more
randomized controlled trials. Meta-analyses of moderate-quality
RCTs.</p>
<p><strong>Level B-NR</strong> — Moderate-quality evidence from 1 or
more well-designed, well-executed nonrandomized studies, observational
studies, or registry studies. Meta-analyses of such studies.</p>
<p><strong>Level C-LD</strong> — Randomized or nonrandomized
observational or registry studies with limitations of design or
execution. Meta-analyses of such studies. Physiological or mechanistic
studies in human subjects.</p>
<p><strong>Level C-EO</strong> — Consensus of expert opinion based on
clinical experience when evidence is insufficient, vague, or
conflicting.</p>
<p></font></p>
<p><font size = 3> RCT: randomized controlled trial; NR: nonrandomized;
LD: limited data; EO: expert opinion </font></p>
<p>  <br/></p>
<br>
<p>
<button type="button" class="btn btn-default btn-workflowr btn-workflowr-sessioninfo" data-toggle="collapse" data-target="#workflowr-sessioninfo" style="display: block;">
<span class="glyphicon glyphicon-wrench" aria-hidden="true"></span>
Session information
</button>
</p>
<div id="workflowr-sessioninfo" class="collapse">
<pre><code>R version 4.2.0 (2022-04-22)
Platform: x86_64-apple-darwin17.0 (64-bit)
Running under: macOS Big Sur/Monterey 10.16

Matrix products: default
BLAS:   /Library/Frameworks/R.framework/Versions/4.2/Resources/lib/libRblas.0.dylib
LAPACK: /Library/Frameworks/R.framework/Versions/4.2/Resources/lib/libRlapack.dylib

locale:
[1] en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-8/en_US.UTF-8

attached base packages:
[1] stats     graphics  grDevices utils     datasets  methods   base     

other attached packages:
 [1] formattable_0.2.1 naniar_0.6.1      forcats_0.5.1     stringr_1.4.0    
 [5] dplyr_1.0.8       purrr_0.3.4       readr_2.1.2       tidyr_1.2.0      
 [9] tibble_3.1.6      ggplot2_3.3.5     tidyverse_1.3.1   Cairo_1.5-15     
[13] countrycode_1.3.1 janitor_2.1.0     kableExtra_1.3.4 

loaded via a namespace (and not attached):
 [1] Rcpp_1.0.8.3      svglite_2.1.0     lubridate_1.8.0   assertthat_0.2.1 
 [5] rprojroot_2.0.3   digest_0.6.29     utf8_1.2.2        cellranger_1.1.0 
 [9] R6_2.5.1          backports_1.4.1   visdat_0.5.3      reprex_2.0.1     
[13] evaluate_0.15     httr_1.4.2        pillar_1.7.0      rlang_1.0.2      
[17] rematch_1.0.1     readxl_1.4.0      rstudioapi_0.13   jquerylib_0.1.4  
[21] rmarkdown_2.14    webshot_0.5.3     htmlwidgets_1.5.4 munsell_0.5.0    
[25] broom_0.8.0       modelr_0.1.8      compiler_4.2.0    httpuv_1.6.5     
[29] xfun_0.30         pkgconfig_2.0.3   systemfonts_1.0.4 htmltools_0.5.2  
[33] tidyselect_1.1.2  workflowr_1.7.0   fansi_1.0.3       viridisLite_0.4.0
[37] withr_2.5.0       tzdb_0.3.0        crayon_1.5.1      dbplyr_2.1.1     
[41] later_1.3.0       grid_4.2.0        jsonlite_1.8.0    gtable_0.3.0     
[45] lifecycle_1.0.1   DBI_1.1.2         git2r_0.30.1      magrittr_2.0.3   
[49] scales_1.2.0      cli_3.2.0         stringi_1.7.6     fs_1.5.2         
[53] promises_1.2.0.1  snakecase_0.11.0  xml2_1.3.3        bslib_0.3.1      
[57] ellipsis_0.3.2    generics_0.1.2    vctrs_0.4.1       tools_4.2.0      
[61] glue_1.6.2        hms_1.1.1         fastmap_1.1.0     yaml_2.3.5       
[65] colorspace_2.0-3  rvest_1.0.2       knitr_1.39        haven_2.4.3      
[69] sass_0.4.1       </code></pre>
</div>
</div>


<!-- Adjust MathJax settings so that all math formulae are shown using
TeX fonts only; see
https://docs.mathjax.org/en/latest/web/configuration.html. This will make
the presentation more consistent at the cost of the webpage sometimes
taking slightly longer to load. Note that this only works because the
footer is added to webpages before the MathJax javascript. -->
<script type="text/x-mathjax-config">
  MathJax.Hub.Config({
    "HTML-CSS": { availableFonts: ["TeX"] }
  });
</script>




</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
